Pharmacokinetics and safety of TP10, soluble complement receptor 1, in infants undergoing cardiopulmonary bypass

American Heart Journal

Volumn 147, Issue 1, 2004, Pages 173-180

  Li, Jennifer S ^a   Sanders, Stephen P ^a   Perry, April E ^a   Stinnett, Sandra S ^a   Jaggers, James ^a   Bokesch, Paula ^b   Reynolds, Laurie ^c   Nassar, Rashid ^a   Anderson, Page A W ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c Pharmaceutical Product Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANTIBIOTIC AGENT; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT INHIBITOR; COMPLEMENT RECEPTOR; DOPAMINE; FLUCONAZOLE; GLUCOSE; HYDROCORTISONE; INSULIN; TP 10; UNCLASSIFIED DRUG;

ARTICLE; BLEEDING; BLOOD VESSEL PERMEABILITY; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; DISEASE COURSE; DRUG BLOOD LEVEL; FEMALE; HEART SURGERY; HUMAN; HYPOTENSION; INFANT; MALE; MULTIPLE ORGAN FAILURE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; THRUSH;

EID: 0348047553     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2003.07.004     Document Type: Article

References (23)

1. Kirklin JK, Westaby S, Blackstone EH, et al. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1983;86:845-57.
2. Seghaye M-C, Duchateau J, Grabitz RG, et al. Complement activation during cardiopulmonary bypass in infants and children: relation to postoperative multiple organ failure. J Thorac Cardiovasc Surg 1993;106:978-87.
3. Seghaye M-C, Grabitz RG, Duchateau J, et al. Inflammatory reaction and capillary leak syndrome related to cardiopulmonary bypass in neonates undergoing cardiac operations. J Thorac Cardiovasc Surg 1996;112:687-97.
4. Weisman HF, Bartow T, Leppo MK, et al. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990;249:146-51.
5. Lazar HL, Hamasaki T, Bao Y, et al. Soluble complement receptor type I limits damage during revascularization of ischemic myocardium. Ann Thorac Surg 1998;65:973-7.
6. Mulligan MS, Yeh CG, Rudolph AR, et al. Protective effects of soluble CR1 in complement-and neutrophil-mediated tissue injury. J Immunol 1992;148:1479-85.
7. Rabinovici R, Sofronski MD, Borboroglu P, et al. Interleukin-2-induced lung injury: the role of complement. Circ Res 1994;74:329-35.
8. Pruitt S K, Bollinger RR, Collins BH, et al. Effect of continuous complement inhibition using soluble complement receptor type 1 on survival of pig-to-primate cardiac xenografts. Transplantation 1997;63:900-2.
9. Naka Y, Marsh HC, Scesney SM, et al. Complement activation as a cause for primary graft failure in an isogeneic rat model of hypothermic lung. Preservation Transplant 1997;64:1248-55.
10. Smith EF III, Griswold DE, Egan JW, et al. Reduction of myocardial reperfusion injury with human soluble complement receptor type 1 (BRL 55730). Eur J Pharmacol 1993;236:477-81.
11. Chai PJ, Nassar R, Oakeley AE, et al. Soluble complement receptor 1 protects heart, lungs, and cardiac myofilament function from cardiopulmonary bypass damage. Circulation 2000;101:541-6.
12. Gillinov AM, DeValeria PA, Winkelstein JA, et al. Complement inhibition with soluble complement receptor type 1 in cardiopulmonary bypass. Ann Thorac Surg 1993;55:619-24.
13. Darling EM, Shearer IR, Nanry K, et al. Modified ultrafiltration in pediatric cardiopulmonary bypass. J Extracorporeal Tech 1994; 26:205-9.
14. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, Inc; 1982.
15. Li JS, Bengur AR, Ungerleider RM, et al. Abnormal left ventricular filling after neonatal repair of congenital heart disease: association with increased mortality and morbidity. Am Heart J 1998;136: 1075-80.
16. Miller BE, Levy JH. The inflammatory response to cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1997;11:355-66.
17. Steinberg JB, Kapelanski DP, Olsen JD, et al. Cytokine and complement levels in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 1993;106:1008-16.
18. Sonntag J, Dähnert I, Stiller B, et al. Complement and contact activation during cardiovascular operations in infants. Ann Thorac Surg 1998;65:525-31.
19. Moen O, Hogisen K, Fosse E, et al. Attenuation of changes in leukocyte surface markers and complement activation with heparin-coated cardiopulmonary bypass. Ann Thorac Surg 1997;63:105-11.
20. Shandelya SML, Kuppusamy P, Herskowitz A, et al. Soluble complement receptor type 1 inhibits the complement pathway and prevents contractile failure in the post-ischemic heart: evidence that complement activation is required for neutrophil-mediated reperfusion injury. Circulation 1993;88:2812-26.
21. Williams GD, Bratton SL, Riley EC, et al. Association between age and blood loss in children undergoing open heart operations. Ann Thorac Surg 1998;66:870-6.
22. Charpie JR, Dekeon MK, Goldberg CS, et al. Postoperative hemodynamics after Norwood palliation for hypoplastic left heart syndrome. Am J Cardiol 2001;87:198-202.
23. Flenady VJ, Gray PH. Chest physiotherapy for preventing morbidity in babies being extubated from mechanical ventilation. Cochrane Database of Systematic Reviews 2002(2):CD000283.